Must have alanine transaminase (ALT) ? 3 × institutional upper limit of normal (ULN) [? 5 × ULN in presence of liver metastases] within 14 days prior to randomization.
Alanine aminotransferase (ALT) ? 2.5 × ULN without liver metastases; must be ? 5 × ULN with liver metastases
ALT ?2.5 x ULN (if liver or bone metastases are present, ?5 x ULN)
Alanine transaminase (ALT) =< 3 x ULN, except for patients with liver metastasis, who are only included if ALT =< 5 x ULN, at the screening visit
Alanine aminotransferase ? 3 x ULN or ? 5 x ULN if liver metastasis is present.
Within 28 days prior to registration: Alanine aminotransferase (ALT) =< 2.5 x ULN (or =< 5 x ULN if liver metastases)
Alanine aminotransferase (ALT) within 2.5 x ULN unless there are liver metastases in which case, ALT within 5 x ULN
Alanine aminotransferase (ALT) within 2.5 x ULN unless there are liver metastases in which case, ALT within 5 x ULN
Determined within 3 weeks of treatment initiation: Alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases
Alanine aminotransferase (ALT) =< 2.5 x ULN (obtained within 28 days prior to first study treatment)\r\n* Subjects with documented liver metastases should have ALT =< 5 x ULN
Obtained =< 14 days prior to randomization: Alanine transaminase (ALT) =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement)
If liver metastasis present, then AST/ALT =< 5 x ULN
CERITINIB INCLUSION CRITERIA: AST (SGOT) and ALT (SGPT) =< 3 x ULN if no liver metastases are present? =< 5 x ULN if liver metastases are present
REGORAFENIB INCLUSION CRITERIA: AST (SGOT) and ALT (SGPT) =< 2.5 x ULN if no liver metastases are present? =< 5 x ULN if liver metastases are present
ENTRECTINIB INCLUSION CRITERIA: AST (SGOT) and ALT (SGPT) =< 3.0 x ULN if no liver metastases are present? =< 5 x ULN if liver metastases are present
Alanine aminotransferase (ALT) =< 2.5 x ULN; =< 5 x ULN if liver metastases are present
Alanine transaminase (ALT) ?2.5 × ULN, or ?5 × ULN if leukemic infiltration of the liver is present
ARM B COHORT 2: AST and ALT =< 2 X ULN; if liver metastases are present then must be < 5 X the ULN
ARM B COHORT 3: AST and ALT =< 2 X ULN; if liver metastases are present then must be < 5 X the ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN; note: if the patient has liver metastases present, then =< 5 x ULN
Alanine aminotransferase (ALT) ? 3 x ULN OR ? 5 x ULN (if liver metastases present)
Liver function tests performed within 3 weeks prior to starting study therapy must have alanine aminotransferase and aspartate aminotransferase =< 2.5 x ULN (or =< 5 x ULN if liver metastases are present)
To be performed within 28 days prior to day 1 of protocol therapy: Alanine aminotransferase (ALT) =< 2.5 x ULN if no liver metastases or =< 5 x ULN if liver metastases
Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) but =< 5.0 x ULN in case of liver metastases; in the presence of liver metastases the liver isoenzyme fraction must be measured and liver isoenzyme fraction (absolute value) must be =< 2 x ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN, or =< 5 x ULN if liver metastases are present
Alanine aminotransferase (ALT) =< 3.0 x ULN for patients without liver metastases; for patients with liver metastasis ALT =< 5 x ULN is allowed
AST and ALT =< 2.5 x ULN (=< 5 x ULN if liver metastases are present) obtained =< 7 days prior to registration
Within 72 h of initiating study treatment: Alanine aminotransferase (ALT) =< 2.5 x ULN OR < 5 x ULN for liver mets
Alanine aminotransferase (ALT) =< 3.0 X ULN (=< 5.0 X ULN if liver metastases are present)
AST/ALT levels ? 2.5 x ULN, or ? 5 x ULN if liver metastases are present.
Alanine transaminase (ALT) =< 3 x ULN (=< 5 x ULN for patients with liver involvement)
Alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastases; for patients with liver metastasis ALT =< 5 x ULN is allowed
Alanine aminotransferase (ALT) =< 2.5 x ULN, or =< 5 x ULN if liver metastases are present
Alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases persist
ALT =< 2.5 x =< 5 x ULN if liver metastases persist
Alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN) or =< 5 x ULN if liver metastases present
Alanine aminotransferase ?3 × ULN for the reference lab (?5 × ULN for subjects with known hepatic metastases)
Alanine transaminase (ALT) ? 3 × institutional upper limit of normal (ULN) [? 5 × ULN in presence of liver metastases] within 14 days prior to randomization.
Alanine aminotransferase (ALT) =< 2.5 x ULN; if liver metastases are present, =< 5 x ULN
Alanine aminotransferase (ALT)? 3 x upper limit of normal (ULN) or ? 5x ULN if liver metastasis is present
Alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases persist
Alanine transaminase (ALT) > 3.0 x ULN, except for patients with liver metastasis who are excluded if ALT > 5.0 x ULN
Alanine aminotransferase (ALT) < 2.5 times ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, ALT < 5.0 times ULN is acceptable; patients with > 3 liver metastases at enrollment will be excluded
Obtained within 28 days prior to registration: Alanine aminotransferase (ALT) =< 2.5 x ULN (subjects with documented liver metastases should have ALT =< 5 x ULN)
Alanine aminotransferase (ALT) < 3 × ULN unless hepatic metastases are present, then < 5 × ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN OR < 5 x ULN for subjects with liver metastases, obtained within 14 days prior to C11-AMT PET scan
Alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5.0 x in case of liver mets), within 2 weeks prior to study start
Alanine transaminase (ALT) =< 3 x ULN (=< 5 x ULN acceptable for pancreatic subjects with known liver metastasis only)
